EM1710E "SGLT 2 Inhibitors Improve CardioRenal Outcomes in DM2 – Get Rid of the Sugar" (IM GR-100617)

Purpose and Overview: Review treatment options for DM2, emphasizing the improved CV and Renal outcomes with SGLT2 Inhibitors.

Download Protocol

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Appreciate the rising incidence of DM2 and increased CV risks with DM2
  • Recall the lack of CV outcome benefits with SU’s, TZD’s, DPP4 inhibitors.
  • Appreciate the improved CV and Renal outcomes with SGLT2 Inhibitors, as well as GLP1 agonists
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
10/11/2017
Course expires: 
11/10/2017
Cost:
$0.00

Photo: David S. Balis, M.D. David S. Balis, M.D.
Professor of Internal Medicine
Division of General Internal Medicine

Available Credit

  • 1.00 AMA

Accreditation Period

Course opens: 
10/11/2017
Course expires: 
11/10/2017

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome